Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., priced an underwritten public offering of 17.5 million common shares and warrants to purchase another 17.5 million common shares at a price of 75 cents for a fixed unit of one common share plus a warrant to purchase an additional common share.